Back to Oncology
Oncologyv2009Evidence-Based

Metroticket Calculator for Hepatocellular Carcinoma (HCC) Survival

Predicts 3 and 5-year survival after liver transplantation for patients with hepatocellular carcinoma (HCC), especially those not meeting Milan Criteria. Uses tumor size, number, and vascular invasion status.

Clinical Input Parameters

mm
Range: 0 — 99 mm
nodules
Range: 0 — 10 nodules
Clinical Assessment
Awaiting Parameters
survival prediction
—Points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Metroticket Calculator for Hepatocellular Carcinoma (HCC) Survival is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Up-to-Seven: Sum of largest tumor diameter (cm) + number of tumors ≤7. Survival prediction based on tumor characteristics matrix.

Clinical Pearls & Practice Notes

  • Developed from 1,556 patients who underwent liver transplantation for HCC in 36 European centers
  • The 'up-to-seven' criteria applies only in absence of macrovascular invasion
  • Provides individualized survival predictions rather than dichotomous in/out criteria
  • Less widely validated than original Milan criteria
  • Metroticket 2.0 also incorporates AFP levels for improved prediction
  • Online calculator available at http://www.hcc-olt-metroticket.org/

Evidence & Literature Citations

  1. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009 Jan;10(1):35-43.
  2. Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology. 2018 Jan;154(1):128-139.
  3. Lei JY, Wang WT, Yan LN. "Metroticket" predictor for assessing liver transplantation to treat hepatocellular carcinoma: a single-center analysis in mainland China. World J Gastroenterol. 2013 Nov 28;19(44):8093-8.

Score Interpretation Ranges

Within Up-to-Seven Criteria0 – 7 pts

Sum of size (cm) + number ≤7, no vascular invasion

Beyond Up-to-Seven Criteria7 – 999 pts

Sum of size (cm) + number >7 or vascular invasion present

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.